<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>jmedicalcasereports</PublisherName>
<JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
<PISSN>I</PISSN>
<EISSN>S</EISSN>
<Volume-Issue>Volume 7; Issue 1</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>(Jan-Feb, 2026)</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>-0001</Year>
<Month>11</Month>
<Day>30</Day>
</PubDate>
<ArticleType>Medical Case Reports</ArticleType>
<ArticleTitle>Asian Experiences in Treating School-Age Children with Bilastine 10 mg Orodispersible Tablets: Cases from Clinical Practice</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>1</FirstPage>
<LastPage>16</LastPage>
<AuthorList>
<Author>
<FirstName>Marysia Tiongco</FirstName>
<LastName>Recto</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
<FirstName>Hiroshi</FirstName>
<LastName>Chantaphakul</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Kent</FirstName>
<LastName>Woo</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Mongkol</FirstName>
<LastName>Lao-Araya</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Wong Hoi</FirstName>
<LastName>Ling</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Rommel C. M.</FirstName>
<LastName>Lobo</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Dinesh</FirstName>
<LastName>Nagrale</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Cuc Thi Kim</FirstName>
<LastName>Nguyen</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Duy Le</FirstName>
<LastName>Pham</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Danilo</FirstName>
<LastName>Poblete</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
<FirstName>Nuntigar</FirstName>
<LastName>Sonsuwan</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>Y</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Allergic rhinitis (AR) and chronic urticaria (CU) are prevalent conditions in children worldwide, including in the Asia-Pacific (APAC) region. These conditions are associated with a substantial impact on health-related quality of life (HRQoL), affecting many aspects of children’s daily functioning. Bilastine 10 mg orodispersible tablet (ODT) is a non-sedating second-generation H1-antihistamine indicated in Asia for the symptomatic treatment of allergic rhinoconjunctivitis (seasonal and perennial) and urticaria in children aged 6–11 years with a body weight of ?20 kg. Real-world evidence on the use of second-generation H1-antihistamines, particularly bilastine 10 mg ODT, in paediatric populations in APAC remains limited. We present thirteen clinical-practice cases from experienced allergologists, dermatologists, ENT specialists, and paediatricians from APAC, discussed at the STAR NETWORK Expert Panel meeting. The cases illustrate the clinical use, efficacy, and safety of bilastine 10 mg ODT once daily in children aged 6–11 years with AR or CU, across a diverse range of clinical aetiologies and symptoms. Once-daily bilastine 10 mg ODT was found to be effective and well-tolerated in managing AR and CU in school-going children, improving symptom control compared with other antihistamines, without any sedative effects or other adverse events.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Asia-Pacific, Bilastine,Chronic Urticaria,Allergic Rhinitis,Orodispersible Tablet</Keywords>
<URLs>
<Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=16080&title=Asian Experiences in Treating School-Age Children with Bilastine 10 mg Orodispersible Tablets: Cases from Clinical Practice</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>Abdullah B, Abdul Latiff AH, Manuel AM, Mohamed Jamli F, Dalip Singh HS, Ismail IH, Jahendran J, Saniasiaya J, Keen Woo KC, Khoo PC, Singh K, Mohammad N, Mohamad S, Husain S, Mand;ouml;sges R. Pharmacological Management of Allergic Rhinitis: A Consensus Statement from the Malaysian Society of Allergy and Immunology. J Asthma Allergy 2022; 15: 983-1003.
Alyami H, Dahmash E, Alyami F, Dahmash D, Huynh C, Terry D, Mohammed AR. Dosage form preference consultation study in children and young adults: paving the way for patient-centred and patient-informed dosage form development. Eur J Hosp Pharm 2017; 24: 332-337.
Bosnic-Anticevich S, Smith P, Abramson M, Hespe CM, Johnson M, Stosic R, Price DB. Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study. BMJ Open 2020; 10: e038870.
Caffarelli C, Duse M, Martelli A, Calvani M, Cardinale F, Chiappini E, Marseglia GL, Miraglia Del Giudice M, Tosca MA, Castagnoli R, Brambilla I, Santoro A, Procaccianti M, Giannetti A, Ricci G, Minasi D. Urticaria in childhood. Acta Biomed 2020; 91: e2020013.
Cheong WK, Chan AWM, Chand;#39;ng CC, Chung WH, Gabriel MT, Godse K, Mitthamsiri W, Nguyen HT, Tiongco-Recto M, Nagrale D. Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia. Drugs Context 2022; 11: 2021-2022.
Chong SN, Chew FT. Epidemiology of allergic rhinitis and associated risk factors in Asia. World Allergy Organ J 2018; 11: 17.
Church DS, Church MK. Pharmacology of antihistamines. World Allergy Organ J 2011; 4: S22-S27.
Church MK, Maurer M, Simons FE, Bindslev-Jensen C, van Cauwenberge P, Bousquet J, Holgate ST, Zuberbier T; Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010; 65: 459-466.
Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergoland;oacute;gica 2005. J Investig Allergol Clin Immunol 2009; 19: 21-26.
Fricke J, and;Aacute;vila G, Keller T, Weller K, Lau S, Maurer M, Zuberbier T, Keil T. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy 2020; 75: 423-432.
Gardiner P, Dvorkin L. Promoting medication adherence in children. Am Fam Physician 2006; 74: 793-798.
Gonand;ccedil;alo M, Gimenand;eacute;z-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, Fomina D, Galvand;agrave;n CA, Godse K, Grattan C, Hide M, Katelaris CH, Khoshkhui M, Kocatand;uuml;rk E, Kulthanan K, Medina I, Nasr I, Peter J, Staubach P, Wang L, Weller K, Maurer M. The global burden of chronic urticaria for the patient and society. Br J Dermatol 2021; 184: 226-236.
Katelaris CH, Lai CKW, Rhee CS, Lee SH, Yun W, Lim-Varona L, Quang VT, Hwang J, Singh H, Kim J, Boyle JM, Dhong HJ, Narayanan P, Vicente G, Blaiss M, Sacks R. Nasal allergies in the Asian-Pacific population: Results from the Allergies in Asia-Pacific Survey. Am J Rhinol Allergy 2011; 25: 3-15.
Kayiran MA, Akdeniz N. Diagnosis and treatment of urticaria in primary care. North Clin Istanb 2019; 6: 93-99.
Kean EA, Adeleke OA. Orally disintegrating drug carriers for paediatric pharmacotherapy. Eur J Pharm Sci 2023; 182: 106377.
Kim HA, Hyun MC, Choi BS. Natural History and Influencing Factors of Chronic Urticaria in Children. Allergy Asthma Immunol Res 2022; 14: 73-84.
Leceta A, Garcand;iacute;a A, Sologuren A, Campo C. Bilastine 10 and 20 mg in paediatric and adult patients: an updated practical approach to treatment decisions. Drugs Context 2021; 10: 2021-5-1.
Lee N, Lee JD, Lee HY, Kang DR, Ye YM. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014. Allergy Asthma Immunol Res 2017; 9: 438-445.
Liu J, Ji X, Pitt S, Wang G, Rovit E, Lipman T, Jiang F. Childhood sleep: physical, cognitive, and behavioral consequences and implications. World J Pediatr 2024; 20: 122-132.
Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, Simmons AL, Wingertzahn MA, Boyle JM. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 2009; 124: S43-S70.
Mennella JA, Spector AC, Reed DR, Coldwell SE. The bad taste of medicines: overview of basic research on bitter taste. Clin Ther 2013; 35: 1225-1246.
Mir E, Panjabi C, Shah A. Impact of allergic rhinitis in school going children. Asia Pac Allergy 2012; 2: 93-100.
Novand;aacute;k Z, Yand;aacute;and;ntilde;ez A, Kiss I, Kuna P, Tortajada-Girband;eacute;s M, Valiente R; “Bilastine Paediatric Safety Study Group”. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol 2016; 27: 493-498.
Parisi GF, Leonardi S, Ciprandi G, Corsico A, Licari A, Miraglia Del Giudice M, Peroni D, Salpietro C, Marseglia GL. Antihistamines in children and adolescents: A practical update. Allergol Immunopathol (Madr) 2020; 48: 753-762.
Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring) 2010; 18: 2398-400.
Ridolo E, Montagni M, Bonzano L, Incorvaia C, Canonica GW. Bilastine: new insight into antihistamine treatment. Clin Mol Allergy 2015; 13: 1.
Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and Angioedema Across the Ages. J Allergy Clin Immunol Pract 2020; 8: 1866-1874.
Schuler Iv CF, Montejo JM. Allergic Rhinitis in Children and Adolescents. Immunol Allergy Clin North Am 2021; 41: 613-625.
Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011; 128: 1139-1150.e4.
Tand;ouml;ndury B, Muehleisen B, Ballmer-Weber BK, Hofbauer G, Schmid-Grendelmeier P, French L, Band;uuml;chi S. The Pictorial Representation of Illness and Self Measure (PRISM) instrument reveals a high burden of suffering in patients with chronic urticaria. J Investig Allergol Clin Immunol 2011; 21: 93-100.
Tuchinda M, Srimaruta N, Habanananda S, Vareenil J, Assatherawatts A. Urticaria in Thai children. Asian Pac J Allergy Immunol 1986; 4: 41-5.
Wasim AU, Miriyala SA, Haward R, Hammoud Z, Agarwal P, Kaka N, Patel N, Sethi Y, Gupta P. Sleep Disturbance and Chronic Urticaria: A Narrative Review of Its Relationship, Treatment and Evolving Literature. Health Sci Rep 2025; 8: e70777.</References>
</References>
</Journal>
</Article>
</ArticleSet>